出典:Wikipedia
出典:『Wikipedia』 (2011/07/01 07:37 UTC 版)
Nemonapride (Emilace) is a atypical antipsychotic approved in Japan for the treatment of schizophrenia. It was launched by Yamanouchi in 1991. Nemonapride acts as a D2 and D3 receptor antagonist, and is also a potent 5-HT1A receptor agonist. It has affinity for sigma receptors.